COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,665 Articles (22,913 medRxiv, 8,752 bioRxiv)

Most recent first Previous |  Page 2001: Articles 20001-20010  | Next

Predicting COVID-19 cases with unknown homogeneous or heterogeneous resistance to infectivity
Shanmugam, R., Ledlow, G., Singh, K. P.
10.1101/2020.12.21.423761 — Posted: 2020-12-21
Mutation Landscape of SARS COV2 in Africa
Nassir, A. A., Musanabaganwa, C., Mwikarago, I.
10.1101/2020.12.20.423630 — Posted: 2020-12-21
Cetylpyridinium chloride-containing mouthwashes reduce in vitro SARS-CoV-2 infectivity
Munoz-Basagoiti, J., Perez-Zsolt, D., Leon, R., Blanc, V., Gispert, J., Clotet, B., Izquierdo-Useros, N.
10.1101/2020.12.21.423779 — Posted: 2020-12-21
Changes in SARS-CoV-2 before the peak in each country, producing unique variants.
Konishi, T.
10.1101/2020.12.18.413344 — Posted: 2020-12-21
pH and Receptor Induced Confirmational Changes- Implications Towards S1 Dissociation of SARS-CoV2 Spike Glycoprotein
Castin, J. E., Gideon, D. A., Sudarsha, K. S., Rosita, S. A.
10.1101/2020.12.21.410357 — Posted: 2020-12-21
In vitro characterization of engineered red blood cells as potent viral traps against HIV-1 and SARS-CoV-2
Hoffmann, M. A. G., Kieffer, C., Bjorkman, P. J.
10.1101/2020.12.20.423607 — Posted: 2020-12-21 Discussion: Onsite
The SARS-CoV-2 spike protein disrupts the cooperative function of human cardiac pericytes - endothelial cells through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease
Avolio, E., Gamez, M., Gupta, K., Foster, R., Berger, I., Caputo, M., Davidson, A. D., Hill, D., Madeddu, P.
10.1101/2020.12.21.423721 — Posted: 2020-12-21
Binding strength and hydrogen bond numbers between Covid-19 RBD and HVR of antibody
Wang, R. T., Xu, A. F., Zhou, Q., Song, T., Xu, K. J., Xu, G.
10.1101/2020.12.21.423787 — Posted: 2020-12-21
Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma
Voss, W. N., Hou, Y. J., Johnson, N. V., Kim, J. E., Delidakis, G., Horton, A. P., Bartzoka, F., Paresi, C. J., Tanno, Y., Abbasi, S. A., Pickens, W., George, K., Boutz, D. R., Towers, D. M., McDaniel, J. R., Billick, D., Goike, J., Rowe, L., Batra, D., Pohl, J., Lee, J., Gangappa, S., Sambhara, S., Gadush, M., Wang, N., Person, M. D., Iverson, B. L., Gollihar, J. D., Dye, J., Herbert, A., Baric, R. S., McLellan, J. S., Georgiou, G., Lavinder, J. J., Ippolito, G. C.
10.1101/2020.12.20.423708 — Posted: 2020-12-21
From infection to immunity: understanding the response to SARS-CoV2 through in-silico modeling
Castiglione, F., Deb, D., Srivastava, A. P., Lio, P., Liso, A.
10.1101/2020.12.20.423670 — Posted: 2020-12-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).